Citius Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Citius Pharmaceuticals, Inc. on December 15, 2017. The filing details a material definitive agreement entered into on the same date regarding a private placement of equity securities.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $6.0 million from the sale of 1,280,360 shares of common stock and warrants.
- Net Proceeds: Approximately $5.45 million after deducting placement agent fees, expenses, and estimated offering costs.
- Share Price: $4.6925 per share for the common stock sold.
- Warrant Terms: Investors received warrants to purchase up to 640,180 shares (50% of shares sold) at an exercise price of $4.63 per share, exercisable for 5.5 years.
- Placement Agent Fees: H.C. Wainwright & Co., LLC received a fee equal to 7% of gross proceeds, plus warrants to purchase 7% of the aggregate shares sold (exercise price $5.8656), and reimbursement for $85,000 in expenses and legal fees.
Material Changes and Use of Proceeds
The company intends to use the net proceeds for general corporate purposes, specifically funding:
- Phase 3 clinical Mino-Lok trial for the treatment of catheter-related bloodstream infections.
- Phase 2b trial of Hydrocortisone-Lidocaine cream for the treatment of hemorrhoids.
- Working capital and capital expenditures.
The common shares were sold pursuant to an effective "shelf" registration statement on Form S-3 (File No. 333-221492), declared effective on December 15, 2017. The warrants were sold unregistered under Section 4(a)(2) and Rule 506 exemptions.
Outlook, Risks, and Unusual Items
The closing of the securities sales is expected to occur on or about December 19, 2017. The filing notes that the warrants are subject to certain ownership limitations and adjustments as provided under their terms. No specific financial risks or contingencies beyond standard transaction terms were detailed in this specific report.
Investor Verification Checklist
- Verify the closing date of the transaction (expected December 19, 2017) and actual net proceeds received.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific ownership limitations and warrant adjustment formulas.
- Confirm the status of the Phase 3 Mino-Lok and Phase 2b Hydrocortisone-Lidocaine trials to assess capital burn rate against the raised funds.
- Check subsequent filings for the actual issuance of the placement agent warrants and any changes to the exercise price.